Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).

Diabetes Obes Metab · 2012 · PMC3466411 · PMID 22564709

Europe PMC DOI

hedged sentence

0.0857

closest p · 1.7× alpha

0.0857

boldest claim

The sentences

a clear trendp = 0.0857so close (0.05 < p ≤ 0.1)

Despite the small changes, there was a clear trend towards weight loss for lixisenatide compared with placebo (p = 0.0857).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.